Safety profile of iloperidone in the treatment of schizophrenia

Bibliography

• Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision making. Expert Opin Pharmacother 2009;10(12):1917-28
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007;68(Suppl 4):8-13
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Vanda Pharmaceuticals. Fanapt (iloperidone) Tablets Full Prescribing Information. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/fanapt.pdf [Last accessed 9 September 2013]
   Google Scholar
• Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmcol 2001;25:904-14
   PubMed Web of Science ®Google Scholar
• Subramanian N, Kalkman HO. Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone. Prog Neuropsychopharmacol Biol Psychiatry 2002;26(3):553-60
   PubMed Web of Science ®Google Scholar
• Szewczak MR, Corbett R, Rush DK, et al. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. J Pharmacol Exp Ther 1995;274:1404-13
   PubMed Web of Science ®Google Scholar
• Bishop JR, Bishop DL. Iloperidone for the treatment of schizophrenia. Drugs Today 2010;46(8):567-79
   PubMed Web of Science ®Google Scholar
• Cutler AJ, Kalali AH, Weiden PJ, et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol 2008;28(2 Suppl 1):S20-8
   PubMed Web of Science ®Google Scholar
• Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol 2008;28(2 Suppl 1):S4-11
   PubMed Web of Science ®Google Scholar
• Kane JM, Lauriello J, Laska E, et al. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol 2008;28(2 Suppl 1):S29-35
   PubMed Web of Science ®Google Scholar
• Lavedan C, Licamele L, Volpi S, et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Molec Psychiatry 2009;14:804-19
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone. J Clin Psychopharmacol 2008;28(2 Suppl 1):S12-19
   PubMed Web of Science ®Google Scholar
• DeHert M, Yu W, Detraux J, et al. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder. CNS Drugs 2012;26(9):733-59
   PubMed Web of Science ®Google Scholar
• Thompson A, Lavedan C, Volpi S. Absence of weight gain association with the HTR2C-759C/T polymorphism in patients with schizophrenia treated with iloperidone. Psychiatry Res 2010;175:271-3
   PubMed Web of Science ®Google Scholar
• Malhotra AK, Zhang JP, Lencz T. Pharmacogenetics in psychiatry: translating research into clinical practice. Mol Psychiatry 2012;17(8):760-9
   PubMed Web of Science ®Google Scholar
• Potkin SG, Preskorn S, Hochfeld M, Meng X. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP 3A4 and a comparison to quetiapine and ziprasidone. J Clin Psychopharmacol 2013;33:3-10
   PubMed Web of Science ®Google Scholar
• Volpi S, Heaton C, Mack K, et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry 2009;14:1024-31
   PubMed Web of Science ®Google Scholar
• Citrome L. Expert Opin Drug Metab Toxicol 2010;6(12):1551-64
   PubMed Web of Science ®Google Scholar
• Freeman S. Iloperidone-induced retrograde ejaculation. Int Clin Psychopharmacol 2013;28:156
   PubMed Web of Science ®Google Scholar
• Guanci N, Aggrawal R, Schleifer S. Atypical neuroleptic malignant syndrome associated with iloperidone administration. Psychosomatics 2012;53(6):603-5
   PubMed Web of Science ®Google Scholar
• Muzyk AJ, Cvelich RG, Kincaid BR, Preud'homme XA. Angioedema occurring in patient prescribed iloperidone and haloperidol: a cross-sensitivity reaction to antipsychotics from different chemical classes. J Neuropsychiatry Clin Neurosci 2012;24(2):E40-1
   PubMed Web of Science ®Google Scholar
• Michelsen JW, Meyer JM. Cardiovascular effects of antipsychotics. Expert Rev Neurother 2007;7:829-39
   PubMedGoogle Scholar
• Kotin J, Wilbert D, Verburg D, Seldinger S. Thioridazine and sexual dysfunction. Am J Psychiatry 1976;133(1):82-5
   PubMed Web of Science ®Google Scholar
• Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96
   PubMed Web of Science ®Google Scholar
• Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158:1774-82
   PubMed Web of Science ®Google Scholar
• Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007;21:911-36
   PubMed Web of Science ®Google Scholar
• Nielsen J, Graff C, Kanters JK, et al. Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs 2011;25(6):473-90
   PubMed Web of Science ®Google Scholar
• Malhotra AK, Correll CU, Chowdhury NI, et al. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry 2012;69(9):904-12
   PubMed Web of Science ®Google Scholar